Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28543534 | 0.80 | CYP2A6 (0.44) | MAPTCYP2A6PKMCHRNA7SLC6A4 | |
| SCHEMBL23645509 | 0.79 | MAPT (0.37) | MAPTLPLLIPGCYP2A6 | |
| SCHEMBL14727554 | 0.78 | LPL (0.43) | MAPTLPLLIPGSLC6A4KDM4E | |
| SCHEMBL657279 | 0.78 | MAP3K7 (0.34) | LPLLIPGCYP2A6 | |
| SCHEMBL25027588 | 0.78 | LPL (0.41) | MAPTLPLLIPGALDH1A1 | |
| SCHEMBL30445860 | 0.78 | MAP3K7 (0.34) | LPLLIPGCYP2A6 | |
| SCHEMBL13927329 | 0.78 | LPL (0.41) | MAPTLPLLIPG | |
| SCHEMBL15574699 | 0.78 | CYP2A6 (0.41) | LPLLIPGCYP2A6 | |
| SCHEMBL23287830 | 0.75 | SNCA (0.43) | MAPTSMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL30080744 | 0.75 | LIPG (0.55) | LPLLIPGCYP2A6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685146-A1 | COMPOUND FOR ORGANIC PHOTOVOLTAIC DEVICES, AND ORGANIC PHOTOVOLTAIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE EACH CONTAINING SAME | Duk San Neolux Co., Ltd. (KR) | 2026-01-28 | — | — | EP | disclosed |
| EP-4536668-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024225617-A1 | COMPOUND FOR ORGANIC PHOTOVOLTAIC DEVICES, AND ORGANIC PHOTOVOLTAIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE EACH CONTAINING SAME | 덕산네오룩스 주식회사 | 2024-10-31 | — | — | WO | disclosed |
| US-20240334823-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING APPARATUS | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-10-03 | — | — | US | disclosed |
| US-12052916-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and electronic apparatus including organic light-emitting apparatus | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-07-30 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| EP-2029602-B1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-04-21 | — | — | EP | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | P2RX5, P2RX3, IL1B | MAPT 438/4885LPL 2158/4885LIPG 3151/4885 |
| US-20240334823-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING APPARATUS | L1CAM, MNS1, NOM1 | MAPT 1313/4885LPL 1230/4885LIPG 2281/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | MAPT 643/4885LPL 3217/4885LIPG 4522/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MAPT 3872/4885LPL 3812/4885LIPG 2732/4885 |
| US-12052916-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and electronic apparatus including organic light-emitting apparatus | L1CAM, MNS1, NOM1 | MAPT 1313/4885LPL 1230/4885LIPG 2281/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MAPT 438/4885LPL 2158/4885LIPG 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.